Frontida Biopharm
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $8.4m | Seed | |
* | N/A | Acquisition | |
Total Funding | CAD11.5m |
Related Content
Recent News about Frontida Biopharm
EditFrontida BioPharm specializes in innovative drug development and manufacturing services, leveraging advanced fluid bed processing technology to reduce production times and enhance efficiency. The company serves pharmaceutical clients by providing solutions that combine multiple active ingredients and delivery rates in a single capsule, utilizing minitabs, beads, granules, and liquid forms. Operating in the pharmaceutical manufacturing market, Frontida's business model focuses on offering high-quality, scalable clinical trial materials and commercial production services. Revenue is generated through contract manufacturing and development services, catering to clients' needs from clinical trials to commercial production. The company's unique technology platform eliminates the need for reformulation after Phase I trials, overcoming technical hurdles and reducing development time by up to 30%.
Keywords: drug development, manufacturing, fluid bed processing, adaptive formulation, pharmaceutical, clinical trials, commercial production, minitabs, scalable materials, high API load.